PlainRecalls
FDA Drug Critical Class I Terminated

Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 200-count bottles (UPC 3 0573 0154 21 5), Pfizer, Madison, NJ 07940

Reported: February 1, 2023 Initiated: December 6, 2022 #D-0181-2023

Product Description

Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 200-count bottles (UPC 3 0573 0154 21 5), Pfizer, Madison, NJ 07940

Reason for Recall

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Details

Units Affected
321,246 tablets
Distribution
Nationwide in the USA.
Location
Warren, NJ

Frequently Asked Questions

What product was recalled?
Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 200-count bottles (UPC 3 0573 0154 21 5), Pfizer, Madison, NJ 07940. Recalled by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon. Units affected: 321,246 tablets.
Why was this product recalled?
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Which agency issued this recall?
This recall was issued by the FDA Drug on February 1, 2023. Severity: Critical. Recall number: D-0181-2023.